PepGen (NASDAQ:PEPG) Cut to Sell at Wall Street Zen

Wall Street Zen lowered shares of PepGen (NASDAQ:PEPG – Free Report) from a hold rating to a sell rating in a research report released on Sunday,Wall Street Zen reports.

Several other brokerages have also weighed in on PEPG. Wedbush lifted their price objective on PepGen from $4.00 to $10.00 and gave the stock an “outperform” rating in a report on Wednesday, November 11th. Bank of America upgraded PepGen from an “underperform” rating to a “neutral” rating and upped their target price for the company from $2.50 to $6.00 in a research note on Tuesday, November 10th. Guggenheim raised their target price on PepGen from $7.00 to $15.00 and gave the stock a “buy” rating in a research report on Friday, November 13th. HC Wainwright reiterated a “buy” rating on shares of PepGen in a research note on Wednesday, September 9th. Finally, Weiss Ratings upgraded shares of PepGen from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Tuesday, September 22nd. Five equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $11.40.

Read Our Latest Report on PepGen

PepGen Stock Performance

NASDAQ PEPG opened at $3.88 on Friday. The firm has a 50-day simple moving average of $2.83 and a 200 day simple moving average of $2.96. PepGen has a twelve month low of $1.31 and a twelve month high of $7.80. The stock has a market cap of $268.73 million, a PE ratio of -3.63 and a beta of 2.02.

PepGen (NASDAQ:PEPG – Get Free Report) last issued its quarterly earnings results on Tuesday, November 10th. The company reported ($0.28) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.27) by ($0.01). Research analysts forecast that PepGen will post -1.13 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in PEPG. Virtu Financial LLC bought a new stake in shares of PepGen in the 3rd quarter valued at approximately $26,000. Jump Financial LLC acquired a new stake in PepGen in the 3rd quarter valued at $114,000. AWM Investment Company Inc. boosted its stake in PepGen by 201.1% in the 3rd quarter. AWM Investment Company Inc. now owns 1,806,419 shares of the company’s stock valued at $4,372,000 after buying an additional 1,206,419 shares in the last quarter. Marshall Wace LLP boosted its stake in PepGen by 136.3% in the 3rd quarter. Marshall Wace LLP now owns 2,049,112 shares of the company’s stock valued at $4,959,000 after buying an additional 1,182,120 shares in the last quarter. Finally, Empowered Funds LLC acquired a new stake in PepGen in the 3rd quarter valued at $205,000. Institutional investors own 58.01% of the company’s stock.

About PepGen

(Get Free Report)

PepGen is a clinical-stage biotechnology company developing oligonucleotide medicines for people with neuromuscular diseases. Its Enhanced Delivery Oligonucleotide (EDO) platform is designed to help deliver these medicines to muscle tissue. The company’s pipeline includes PGN-EDO51, an investigational exon-skipping therapy for Duchenne muscular dystrophy in patients whose genetic mutations are amenable to exon 51 skipping, and PGN-EDODM1, an investigational candidate for myotonic dystrophy type 1.

Further Reading

Analyst Recommendations for PepGen (NASDAQ:PEPG)

Receive News & Ratings for PepGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PepGen and related companies with MarketBeat.com's FREE daily email newsletter.